Keywords: Liver, fMRI, Hepatocellular Carcinoma； Immunotherapy； Nanocarrier; IVIM-MRI; Tumor Microenvironment
Motivation: To enhance the efficacy of hepatocellular carcinoma immunotherapy using a nanocarrier and to explore IVIM-MRI for monitoring the tumor immune microenvironment.
Goal(s): To synthesize iRGD-targeted liposomes to enhance the treatment efficacy of hepatocellular carcinoma and to develop effective biomarkers for the tumor microenvironment.
Approach: We synthesized iRGD-modified liposomal co-encapsulating Lenvatinib and BMS-202. IVIM-MRI was performed before and at 6 and 12 days after treatments, followed by pathological examination after the final scan.
Results: iRGD-lip@Len/BMS-202 promotes tumor vascular normalization and effectively activates an anti-tumor immune response. Importantly, the derived parameters D* and f are significantly correlated with tumor vascular normalization and immune activation.
Impact: The iRGD-targeted dual-drug liposomal nanoparticles exhibited potent synergistic anti-tumor effects. Additionally, IVIM-MRI facilitated the monitoring of changes in the tumor microenvironment, with the D* and f parameters serving as valuable indicators for evaluating tumor vascular network and immune microenvironment modulation.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords